Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in retinal bipolar cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7584
Sealed predictions
- MPP2 in oligodendrocytes, braak-0.80 (p 0.009) → -0.81 (p 0.008)held
- MPP2 in dopamine neurons, braak-0.16 (p 0.685) → -0.37 (p 0.329)receipt 7591
Swarm cases
receipt 7591: MPP2 in dopamine neurons, braak
- power
- full sample -0.29 (p 0.250, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.250, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.232, n 18). could be the mix.
- skeptic
- leave-one-out range -0.48 to -0.22, sign flips 0; without severely affected donors -0.29 (p 0.250, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.75 (p 3.3e-4, n 18) vs -0.29 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MPP2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MPP2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.38 p 0.183 (needs p < 2.8e-4)
Receipts
loading the receipts